Alnylam Pharmaceuticals (ALNY) Other Operating Expenses (2012 - 2026)

Alnylam Pharmaceuticals (ALNY) has 11 years of Other Operating Expenses data on file, last reported at $298.5 million in Q2 2026.

• Quarterly Other Operating Expenses rose 108.78% year-over-year to $298.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $977.4 million (up 142.71% YoY) and the FY2025 annual result came in at $681.9 million, up 110.86% from the prior year.
• Other Operating Expenses climbed to $298.5 million in Q2 2026, from $211.1 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $298.5 million in Q2 2026 to a low of $35.6 million in Q1 2022.
• A 5-year average of $110.8 million and a median of $84.8 million in 2023 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2024 — Other Operating Expenses retreated 19.56% — and 2026, when it surged 197.18%.
• Tracing ALNY's Other Operating Expenses over 5 years: stood at $51.3 million in 2022, then jumped by 67.48% to $85.9 million in 2023, then increased by 19.75% to $102.8 million in 2024, then surged by 160.39% to $267.7 million in 2025, then rose by 11.48% to $298.5 million in 2026.
• The last three Other Operating Expenses figures came in at $298.5 million (Q2 2026), $211.1 million (Q1 2026), and $267.7 million (Q4 2025), per Business Quant data.